Have always been fascinated by the idea that some b/tsDMARDs might have effects on pain and fatigue beyond inflammation control. Baricitinib data in RA before, & now this from guselkumab. Substantial effect on pain beyond SJC/CRP attributable? POS1030 #EULAR2022 #IL23 @RheumNow https://t.co/fxqIGnlkwU